Alucent Biomedical has received US Food and Drug Administration (FDA) approval to proceed with a phase 1 clinical trial to evaluate the safety and efficacy of its Natural Vascular Scaffolding (NVS) technology. The therapy is designed to treat peripheral arterial disease (PAD) of the lower extremities, a condition that affects over 200 million people worldwide.
According to a press release, the Alucent NVS vessel restoration system with photoactivated linking combines standard angioplasty with linking of the structural proteins in the wall of a blood vessel. The intervention is designed to deliver immediate restoration of the vessel’s lumen and sustained improvement of blood flow, without the introduction of a foreign implant, such as a metallic stent, into the patient’s body. Because there is no rigid foreign material, the arterial wall has the potential to retain its natural functionality and flexibility, and avoid the complications of permanent stents. Alucent NVS photoactivated linking is also designed to mitigate the adverse effects of angioplasty, such as vessel recoil. Sustained, improved blood flow is expected to result in pain relief, limb preservation, and an improved quality of life for patients.
“FDA approval to commence human clinical testing allows us to move this revolutionary therapy into PAD patients, many of whom are in acute need of a better and more durable alternative to currently available treatments,” comments Myles Greenberg, CEO of Alucent.
Preclinical testing of NVS in animal studies has shown acute and long-term safety and patency without the pro-inflammatory and mechanical risks of placing a rigid foreign implant into the blood vessel.
“Alucent NVS is a novel and disruptive medical therapy that may promote better clinical outcomes in patients with symptomatic femoropopliteal atherosclerosis without the use of a metallic implant. Moreover, given the novel nature of this therapy, which in animal models was able to restore vessel wall architecture, it has the potential to dramatically improve quality of life in patients with peripheral arterial disease”, says Krishna Rocha-Singh, chief scientific officer at HSHS St John’s Prairie Heart Institute in Springfield, USA, and chief medical advisor of Alucent Biomedical.
Enrollment for the phase 1 clinical trial is expected to begin in Q1 2020. Up to 15 patients will be enrolled across five research sites, including the Cardiovascular Institute of the South in Houma, USA, and the Wellmont Hollston Valley Medical Center in Kingsport, USA.
Duc Tin Clinic
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389